Clarient Diagnostic Services, Inc.

Applied Genomics, Inc.

The Uab Research Foundation

Robert S Seitz

Douglas T Ross

Brian Z Ring

Rodney A Beck

Tyler O Kirby

Warner Huh

Methods of using TLE3 as a marker for predicting the likelihood that a patient's cancer will respond to chemotherapy. Methods of using TLE3 as a marker for selecting a chemotherapy for a cancer.

TLE3 as a marker for chemotherapy

Methods and reagents for classifying HER2+ breast tumors and for identifying new HER2+ breast tumor classes and subclasses. Methods for correlating tumor class or subclass with therapeutic regimen or outcome, for identifying appropriate (new or known) therapies for particular classes or subclasses, and for predicting outcomes based on class or subclass. New therapeutic agents and methods for the treatment of HER2+ breast cancer.

Reagents and methods for use in cancer diagnosis, classification and therapy

Methods and reagents for classifying tumors and for identifying new tumor classes and subclasses. Methods for correlating tumor class or subclass with therapeutic regimen or outcome, for identifying appropriate (new or known) therapies for particular classes or subclasses, and for predicting outcomes based on class or subclass. New therapeutic agents and methods for the treatment of cancer.

Growing community of inventors

Hampton Cove, AL, United States of America

Robert S Seitz